BioNTech's stock surged 187% in one year — and there's more upside, says Berenberg

Share
Key Points
  • German pharmaceutical company BioNTech, together with U.S. biotech giant Pfizer, co-developed a Covid-19 vaccine which has been authorized for emergency use by numerous countries.
  • "I think this year will be a catalyst-rich year," said Shu, a senior biotech analyst at Berenberg Capital Markets. "The Covid vaccine definitely is part of the story."
Vaccine ampoules stand on a table at the Harz Vaccination Centre.
Matthias Bein | picture alliance | Getty Images

(This story is for CNBC PRO subscribers only.)

BioNTech's shares have risen more than 180% in the last 12 months and hit a record high in December, but one analyst from investment bank Berenberg said there's more upside in the coming year.

The German pharmaceutical company, together with U.S. pharmaceutical giant Pfizer, co-developed a Covid-19 vaccine which has been authorized for emergency use by regulators, including those in the U.S., U.K. and European Union.

"I think this year will be a catalyst-rich year," said Zhiqiang Shu, a senior biotech analyst at Berenberg Capital Markets.

"The Covid vaccine definitely is part of the story," he told CNBC's "Squawk Box Asia" on Tuesday.

More In Pro News and Analysis

CNBC ProStock market live updates: Stocks hit records, Morgan Stanley bullish on Apple, bitcoin under pressure
CNBC ProThese stocks reporting earnings next week almost always beat estimates and gain
CNBC ProGM may be engineering one of the best turnarounds in business history, Morgan Stanley's Jonas says